InMed Pharmaceuticals (INM) Total Debt (2021 - 2022)

InMed Pharmaceuticals' (INM) quarterly Total Debt came in at $29312.0 in Q1 2022, down 50.0% quarter-over-quarter from $58624.0 in Q4 2021.

InMed Pharmaceuticals (INM) Total Debt (2021 - 2022) Analysis & Trends

InMed Pharmaceuticals' Total Debt history runs 2 years deep, the most recent figure standing at $29312.0 for Q1 2022.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Debt (Qtr)
1 Haleon 87.22 Bn 85.35 Bn - 11.45 Bn
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn 16.63 Bn
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn 9.05 Bn
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn 28.76 Bn
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn -
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn - 7.15 Bn
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn 14.34 Bn
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn -
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn 3.81 Bn
10 InMed Pharmaceuticals 307,858.50 -4.93 Mn - -

Historic Data

Download Data
DateValue
Mar 31, 2022 29,312.00
Dec 31, 2021 58,624.00